Contemp Clin Trials by Chavula, Charity et al.
Stopping the Control Arm in Response to the DSMB: Mother’s
Choice of HIV Prophylaxis during Breastfeeding in the BAN
Study
Charity Chavulaa, Dustin Longb, Enalla Mzembea, Dumbani Kayiraa, Charles Chaselaa,
Michael G. Hudgensb, Mina Hosseinipoura,c, Caroline C. Kingd, Sascha Ellingtond, Margret
Chigwenembea, Denise J. Jamiesond, Charles van der Horstc, and for the BAN Study Team
Charity Chavula: charitychavula2001@yahoo.co.uk; Dustin Long: dustinl@email.unc.edu; Enalla Mzembe:
enallamzembe@yahoo.co.uk; Dumbani Kayira: dumbanikayira@yahoo.com; Charles Chasela:
cchasela@unclilongwe.org; Michael G. Hudgens: mhudgens@bios.unc.edu; Mina Hosseinipour:
mina_hosseinipour@med.unc.edu; Caroline C. King: ccking@cdc.gov; Sascha Ellington: sellington@cdc.gov; Margret
Chigwenembe: mchigwenembe@unclilongwe.org; Denise J. Jamieson: djamieson@cdc.gov; Charles van der Horst:
cvdh@med.unc.edu
aUNC Project, Lilongwe, Malawi.
bDepartment of Biostatistics, School of Public Health, University of North Carolina, Chapel Hill,
North Carolina, U.S.A.
cDivision of Infectious Diseases, School of Medicine, University of North Carolina, Chapel Hill,
North Carolina, U.S.A.
dDivision of Reproductive Health, National Center for Chronic Disease Prevention and Health
Promotion, US Centers for Disease Control and Prevention, Atlanta, Georgia, U.S.A.
Abstract
The Data and Safety Monitoring Board (DSMB) for the Breastfeeding, Antiretrovirals, and
Nutrition study, a clinical trial aimed to prevent postnatal HIV transmission, recommended halting
randomization to the enhanced standard-of-care (control) arm. The 67 mother-infant pairs on the
control arm and less than 21 weeks postpartum at the time of the DSMB recommendation were
read a script informing them of the DSMB decision and offering them the the maternal or infant
antiretroviral interventions for the remainder of the 28-week breastfeeding period. This paper
describes the BAN study response to the DSMB decision and what the women on the control arm
chose, when given a choice to start the maternal or infant antiretroviral interventions.
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Introduction
Breast milk transmission accounts for almost half of the estimated 420,000 HIV infections
among children, annually [1]. Most of these infections occur in sub-Saharan Africa, where
replacement feeding from birth is neither feasible nor safe due to cost, lack of a safe water
supply, and increased risk of infant morbidity and mortality [2, 3].
Prevention of HIV transmission during breastfeeding was evaluated in the Breastfeeding,
Antiretrovirals, and Nutrition (BAN) study that randomized mothers and their infants to one
of three study arms—with 28-weeks of postnatal antiretroviral prophylaxis given to the
mother, infant, or neither [4, 5]. In March 2008, the Data and Safety Monitoring Board
(DSMB) overseeing the BAN study recommended halting enrollment to the control arm
based on interim findings that HIV transmission was significantly reduced among infants on
one of the antiretroviral intervention arms compared to the control arm. The BAN Study
stopped enrollment to the control arm, and all women who were on that arm and less than 21
weeks postpartum were offered the maternal or infant antiretroviral interventions for the
remainder of the 28-week breastfeeding period. Thus, the BAN Study provides a case study
in how to respond to a DSMB recommendation and offers an opportunity to evaluate
women’s choice regarding initiation of antiretroviral prophylaxis for prevention of postnatal
HIV transmission.
Methods
At an urban healthcare facility in Lilongwe, Malawi, the BAN Study enrolled HIV-infected
mothers who met prenatal and postnatal screening criteria (www.thebanstudy.org;
ClinicialTrials.gov number, NCT00164736) [4, 5]. The prenatal criteria included ≥14 years
of age, CD4 cell count ≥250/mm3 (≥200/mm3 before July 24, 2006), hemoglobin ≥7 g/dl,
alanine aminotransaminase <2.5 times the upper limit of normal, and no serious
complications of pregnancy. The postnatal criteria included infant birth weight ≥2000 g, no
severe congenital malformations or other conditions incompatible with life, and no maternal
condition which would preclude initiation of the antiretroviral prophylaxis. To prevent
intrapartum HIV transmission, all mothers and their infants received a single dose of
nevirapine at delivery, the standard of care at the time, and daily zidovudine and lamivudine
for one week postpartum [6, 7]. Within 7 days of delivery, mother-infant pairs were
randomized according to a factorial design to one of two nutritional study arms to prevent
maternal depletion and one of three postnatal antiretroviral arms—with 28 weeks of
antiretrovirals given to the mother, infant or neither—to prevent HIV transmission during
breastfeeding. The maternal antiretroviral regimen was a standard triple drug regimen. The
infant regimen was 28 weeks of daily nevirapine syrup with dosage increasing with age. All
enrolled participants received a family maize supplement, medical care, and counseling on
rapid breastfeeding cessation from 24 to 28 weeks. The mother-infant pairs were followed
for up to 14 postpartum visits through 48 weeks after delivery. Infants were tested for HIV
infection at birth and weeks 2, 12, 28 and 48, and those who were HIV positive were
referred for care.
On March 26, 2008, an independent DSMB of the National Institute of Allergy and
Infectious Diseases met and reviewed interim results from the first 1,857 mother-infant pairs
who had received treatment assignment. The report from this meeting stated that 1) the HIV
transmission rate was significantly higher among infants on the control arm compared to
infants on one of the antiretroviral intervention arms (later found to be the infant nevirapine
arm) and 2) the DSMB recommended stopping enrollment to the control arm, but continuing
randomization to both the antiretroviral intervention arms. The BAN study implemented the
DSMB recommendations on March 27, 2008. In addition, the BAN Study team offered
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mothers currently on the control arm and less than 21 weeks postpartum the choice of the
maternal or infant antiretroviral intervention through 28 weeks postpartum. Investigators
prepared a script, in local Chichewa, explaining the DSMB recommendations (English
translation shown in Appendix). The revised protocol was approved by the Malawi National
Health Science Research Committee and institutional review boards at University of North
Carolina at Chapel Hill and the U.S. Centers for Disease Control and Prevention. Beginning
April 14, 2008, women were read the script informing them of their choice to stay on the
control arm or initiate one of the two antiretroviral interventions, and specimens were
collected to determine maternal CD4 count and infant HIV status. The mothers returned one
week later. Mother-infant pairs with either a maternal CD4 count <250 cells/µl or an HIV-
infected infant were referred for care, but remained in study follow-up, while the remaining
mother-infant pairs were offered their chosen intervention until 28-weeks postpartum or
breastfeeding cessation, whichever occurred first.
Exact methods were used to determine factors associated (p<0.05) with choosing an
antiretroviral intervention over remaining on the control arm in univariate logistic regression
using SAS version 9.2. Maternal factors evaluated were age group, education, marital status,
parity, CD4 count at screening, body mass index at 4 weeks post-partum, and occurrence of
clinical or laboratory serious adverse events [5]. Infant characteristics evaluated were history
of a laboratory or clinical adverse event and age in weeks and weight-for-length z-score at
the time of decision.
Results
On March 26, 2008, 97 mother-infant pairs were on the control arm and within the 28-week
postpartum intervention period (Figure 1). Of these, 26 were beyond 21 weeks postpartum
and 4 were lost to follow-up prior to April 14, 2008. Given the choice to switch to either the
maternal or infant antiretroviral intervention, about half (47.8%, n=32) chose to stay on the
control arm. Mothers who chose an antiretroviral intervention (n=35) were significantly
more likely to choose the maternal (85.7%) over the infant (14.3%) regimen (p<0.001).
None of the maternal factors considered were associated with choosing an antiretroviral
intervention (Table 1). Although not significant, a higher proportion of the women who
chose an intervention (48.6%, n=17) had more than a primary school education compared to
those who chose to remain on the control arm (28.1%, n=9). Neither the mother’s CD4
count at screening nor her experience of an adverse event postpartum was associated with
choosing an antiretroviral intervention.
The odds of a mother choosing an antiretroviral intervention decreased 20% for each week
of infant age (p<0.001) (Table 1). Infant weight-for-length at the time of the choice was also
associated with choosing an antiretroviral intervention (p=0.002). Mothers of infants with
higher weight-for-length were more likely to choose an intervention compared to mothers of
infants with lower weight-for-length (OR=2.33 for one z-score difference in weight-for-
length). Age and weight-for-length remained significant in a multivariable model, adjusting
each variable for the other (age p-value =0.001; weight-for-length p=0.006). Serious adverse
events among infants prior to mothers choosing whether to switch to an antiretroviral
intervention was not associated with the mother’s decision.
Discussion
Our study team responded swiftly to the DSMB recommendations but faced the hurdle of
what to do with women already randomized to the control arm. We decided to inform the
women and offer them a choice. Almost half of the mothers in the BAN study who were
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offered the maternal or infant antiretroviral interventions chose to remain on the control arm.
Mothers were more likely to choose an intervention if they were in the earlier postpartum
period, with a longer time remaining for breastfeeding and prophylaxis use. The only other
independent factor associated with choosing an intervention was infant weight-for-length,
which may be an indicator of general well-being of the infant and potentially their mother.
Initiation of the BAN study interventions at delivery has demonstrated efficacy for
prevention of HIV transmission during breastfeeding [5], but the effectiveness of these
regimens when started later in the postnatal period remains unclear. Women enrolled in the
BAN study were receptive to randomization to an antiretroviral intervention, and when
given the choice to start an intervention, they may have intuitively chosen what makes sense
scientifically: the less time remaining on the study, the lower potential benefit of the
antiretroviral prophylaxis compared to the risk for side effects and resistance upon stopping.
Among mothers choosing an intervention, significantly more chose the maternal regimen.
Knowledge of the benefits of antiretroviral therapy for treatment of HIV disease may have
increased the motivation for the maternal regimen. Alternatively, mothers may prefer that
they assume any risk of antiretroviral prophylaxis rather than their infants. To better
understand mothers’ motivations, future research should ask women why they prefer one
method over another.
Conclusions
Early stopping of randomization to a control arm upon evidence for clinical benefit of an
intervention arm in a factorial design creates ethical and scientific difficulties as well as
opportunities. Foremost, investigators must reassess the best interests of the participants on
the control arm and rapidly respond accordingly. If investigators decide to offer control
participants the option of study interventions, they can evaluate participant preference. The
World Health Organization recently issued new guidelines for the prevention of mother-to-
child transmission recommending the provision of antiretrovirals to the mother or infant
during breastfeeding to prevent postnatal HIV transmission [8]. The BAN study suggests
that, when given the choice of postnatal antiretroviral prophylaxis, mothers may prefer the
maternal regimen.
Abbreviations
DSMB Data Safety and Monitoring Board
BAN Breastfeeding, Antiretrovirals, and Nutrition Study
Acknowledgments
Grant support:
The BAN study was supported by grants from the Prevention Research Centers Special Interest Project of the
Centers for Disease Control and Prevention (CDC) (SIP 13-01 U48-CCU409660-09, SIP 26-04 U48-DP000059-01,
and SIP 22-09 U48-DP001944-01), the National Institute of Allergy and Infectious Diseases (NIAID P30-
AI50410), the University of North Carolina Center for AIDS Research (P30-AI50410), and the NIH Fogarty AIDS
International Training and Research Program (DHHS/NIH/FIC 2-D43 Tw01039-06). The CDC was the primary
sponsor of the study; CDC representatives were part of the study team and therefore were involved in the study
design, coordination, data collection, data analysis, data interpretation, and writing of the report. The study group
had full access to all data in the study and had shared responsibility for the analysis and interpretation of the data
and decision to submit for publication. The antiretrovirals used in the BAN study were donated by Abbott
Laboratories, GlaxoSmithKline, Boehringer-Ingelheim, Roche Pharmaceuticals and Bristol-Myers Squibb. The
manufacturers had no role in the design of the study, the collection or analysis of the data, or the decision to submit
the manuscript for publication. The Call to Action PMTCT program was supported by the Elizabeth Glaser
Chavula et al. Page 4
Contemp Clin Trials. Author manuscript; available in PMC 2013 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Pediatric AIDS Foundation Call to Action and International Leadership Awards, UNICEF, World Food
Programme, Malawi Ministry of Health, Johnson and Johnson, and USAID.
The BAN Study was carried out in accordance with the Code of Ethics of the World Medical Association
(Declaration of Helsinki) for experiments involving humans.
The BAN Study Team:
We are grateful to the BAN Study Team at University of North Carolina, Chapel Hill, Centers for Disease Control
and Prevention, Atlanta, and UNC Project team in Lilongwe including: Linda Adair, Yusuf Ahmed, Mounir Ait-
Khaled, Sandra Albrecht, Shrikant Bangdiwala, Ronald Bayer, Margaret Bentley, Brian Bramson, Emily Bobrow,
Nicola Boyle, Sal Butera, Charles Chasela, Charity Chavula, Joseph Chimerang’ambe, Maggie Chigwenembe,
Maria Chikasema, Norah Chikhungu, David Chilongozi, Grace Chiudzu, Lenesi Chome, Anne Cole, Amanda
Corbett, Amy Corneli, Ann Duerr, Henry Eliya, Sascha Ellington, Joseph Eron, Sherry Farr, Yvonne Owens
Ferguson, Susan Fiscus, Shannon Galvin, Laura Guay, Chad Heilig, Irving Hoffman, Elizabeth Hooten, Mina
Hosseinipour, Michael Hudgens, Stacy Hurst, Lisa Hyde, Denise Jamieson, George Joaki (deceased), David Jones,
Zebrone Kacheche, Esmie Kamanga, Gift Kamanga, Coxcilly Kampani, Portia Kamthunzi, Deborah Kamwendo,
Cecilia Kanyama, Angela Kashuba, Damson Kathyola, Dumbani Kayira, Peter Kazembe, Caroline C. King,
Rodney Knight, Athena P. Kourtis, Robert Krysiak, Jacob Kumwenda, Edde Loeliger, Misheck Luhanga, Victor
Madhlopa, Maganizo Majawa, Alice Maida, Cheryl Marcus, Francis Martinson, Navdeep Thoofer, Chrissie Matiki
(deceased), Douglas Mayers, Isabel Mayuni, Marita McDonough, Joyce Meme, Ceppie Merry, Khama Mita,
Chimwemwe Mkomawanthu, Gertrude Mndala, Ibrahim Mndala, Agnes Moses, Albans Msika, Wezi Msungama,
Beatrice Mtimuni, Jane Muita, Noel Mumba, Bonface Musis, Charles Mwansambo, Gerald Mwapasa, Jacqueline
Nkhoma, Richard Pendame, Ellen Piwoz, Byron Raines, Zane Ramdas, John Rublein, Mairin Ryan, Ian Sanne,
Christopher Sellers, Diane Shugars, Dorothy Sichali, Wendy Snowden, Alice Soko, Allison Spensley, Jean-Marc
Steens, Gerald Tegha, Martin Tembo, Roshan Thomas, Hsiao-Chuan Tien, Beth Tohill, Charles van der Horst,
Esther Waalberg, Jeffrey Wiener, Cathy Wilfert, Patricia Wiyo, Innocent Zgambo, and Chifundo Zimba.
Finally and most especially, we thank all the women and infants that participated in the BAN study.
Appendix
“Dear BAN Study Participant:
Thank you for taking part in this important study. UNC Project appreciates your help. As
you know, we are gathering information so we can better understand HIV infection. Part of
this study is trying to find the best way to prevent your baby from getting HIV through
breastfeeding. No one at present knows the best way to protect babies when the mother is
infected with HIV. In BAN all mothers get one dose of Nevirapine at delivery. Also, all
mothers and babies get 7 more days of HIV medicines. This is to prevent the baby from
getting infected with HIV at birth and in the first 7 days of breastfeeding.
In BAN we are studying whether there are ways of preventing your baby from getting HIV.
We do this by either giving HIV medicines to you or your baby or neither after the first 7
days. For the last two and a half years, an independent committee has been looking at our
results on a regular basis. They are looking to see if one of those groups is doing better than
the other. On March 26th 2008, they met and decided that we should no longer put mothers
or infants in the group where neither receives extra medicines. Instead, they should be
offered the chance to be in one of the other groups. They decided this because there is less
chance of the baby getting HIV from breastmilk when either the mother or infant take
medicine during breastfeeding. Women and infants who take these medicines can become
sick from them. However, the benefit of taking the medicines is more than the risk of
becoming sick. Please remember, babies who get the Neverapine dose at delivery with 7days
of HIV medications have a smaller chance of getting HIV compared to the Malawi standard
of only taking a single dose of nevirapine.
Since you were in the group that only took HIV medicines for the first 7 days, you can now
choose between one of these three options:
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1. You can continue to be followed on the study without you or your baby starting the new
medicines. This will mean there is a small risk of your baby getting HIV through the breast
milk but no side effects from the medicines.
OR
2. You can begin giving your baby nevirapine syrup until you stop breastfeeding or 28
weeks whichever comes first. There may be a smaller risk of your baby getting HIV.
However, there is a small chance the medicines may not agree with your baby and may
make him sick.
OR
3. You can begin taking the HIV medicines Combivir (1 tablet) and Aluvia (2 tablets). You
would take these medicines each twice a day until you stop breastfeeding or 28 weeks,
whichever comes first. This will mean that your baby may have a smaller chance of getting
HIV. But you will have a small chance of the medicines not agreeing with you and could
make you sick.
The chance of your child getting HIV depends on how long you breastfeed. It also depends
on how long you will keep breastfeeding. If your child is already 24 weeks switching may
not make a difference since the child would be stopping breast feeding soon anyway.
If you have understood this letter, we ask you to sign it. It states that you understand this
information. Also, please circle your choice.”
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Figure 1.
Implications of halting enrollment to the control antiretroviral arm of the BAN Study.
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Table 1
Maternal and infant characteristics of mother-infant pairs who chose an antiretroviral intervention compared to
those remaining on the control arm in the BAN Study.
Number Choosing to:
Start
Antiretrovirals
Remain on
Control Arm
Odds Ratio (95% CI)a P-value a
Maternal Factorsb
Age 0.68
    < 23 years 14 10 Ref
    23 – 27 years 9 11 0.59 (0.15, 2.26)
    > 27 years 12 11 0.78 (0.21, 2.86)
Marital status 1.00
    Other 2 1 Ref
    Married 33 31 0.54 (0.00, 10.80)
Total number of pregnancies 0.28
    1 3 4 Ref
    2 14 7 2.57 (0.33, 22.82)
    3+ 18 21 1.14 (0.17, 8.83)
Education level of mother 0.14
    ≤ Primary education 18 23 Ref
    > Primary education 17 9 2.38 (0.78, 7.63)
BMI 4 weeks postpartum 0.58
    < 21.5 kg/m2 10 10 Ref
    21.5 – 24 kg/m2 12 14 0.86 (0.23, 3.21)
    > 24 kg/m2 13 8 1.61 (0.40, 6.73)
BMI at time of choice 0.42
    < 21.5 kg/m2 10 11 Ref
    21.5 – 24 kg/m2 12 14 0.94 (0.26, 3.47)
    > 24 kg/m2 13 7 2.00 (0.49, 8.66)
CD4 0.46
    < 400 11 12 Ref
    400 – 500 10 12 0.91 (0.24, 3.42)
    > 500 14 8 1.88 (0.50, 7.46)
Maternal SAEc prior to choice 0.66
    No 33 29 Ref
    Yes 2 3 0.59 (0.05, 5.53)
Infant Factors
Age of infant at choice (weeks) 0.80 (0.69, 0.90) <0.001
Weight-for-lengthd at choice 2.33 (1.26, 6.64) 0.002
Infant SAEc prior to choice 0.56
    No 26 26 Ref
    Yes 9 8 1.49 (0.41, 5.88)
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a
Odds ratios, confidence intervals (CIs), and p-values were generated by exact logistic regression with each factor as the sole covariate.
b
Maternal characteristics assessed at baseline (enrollment) visit unless stated otherwise.
c
SAE = serious adverse event.
d
Weight-for-height Z-Score.
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